KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $580.2 million.

  • Biomarin Pharmaceutical's Cost of Revenue fell 25.67% to $140.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $577.9 million, marking a year-over-year decrease of 0.71%. This contributed to the annual value of $580.2 million for FY2024, which is 9.05% up from last year.
  • As of FY2024, Biomarin Pharmaceutical's Cost of Revenue stood at $580.2 million, which was up 9.05% from $532.1 million recorded in FY2023.
  • Biomarin Pharmaceutical's Cost of Revenue's 5-year high stood at $580.2 million during FY2024, with a 5-year trough of $470.5 million in FY2021.
  • Moreover, its 3-year median value for Cost of Revenue was $532.1 million (2023), whereas its average is $538.4 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 45.85% in 2020, then declined by 10.25% in 2021.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Cost of Revenue stood at $524.3 million in 2020, then decreased by 10.25% to $470.5 million in 2021, then grew by 6.91% to $503.0 million in 2022, then rose by 5.77% to $532.1 million in 2023, then climbed by 9.05% to $580.2 million in 2024.